Armstrong Asia of Singapore selected as NeuroSigma’s manufacturing partner
NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced completion of an approximately $1 million investment into a high-volume manufacturing line for the second-generation Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating pediatric attention-deficit/hyperactivity disorder (ADHD). NeuroSigma’s manufacturing partner for the project is Singapore-based Armstrong Asia, a leading manufacturer for the medical, automotive and consumer electronics industries, with operations across Asia and partnerships around the globe. The investment was led by Checkmate Capital, a strategic advisory and investment group headquartered in Pasadena, California. The investment and manufacturing project are part of a collaboration between Armstrong and Checkmate, stemming from their July 2025 strategic memorandum of understanding (MOU) focused on the development and manufacturing of new technologies, particularly in the medical device industry.
Health Technology Insights: Rocket Doctor AI Partners to Boost AI Clinical Support in Alberta
“This investment enables cost-efficient and scalable manufacturing of the second-generation Monarch eTNS device,” said Colin Kealey, M.D., President and CEO of NeuroSigma. “As we move into 2026, we look forward to working with Armstrong Asia to deliver this innovative product to patients and families throughout the world.”
“We would like to thank NeuroSigma and Checkmate for selecting Armstrong as their manufacturing partner for the second-generation Monarch eTNS device,” added Phyllis Ong, CEO of Armstrong Asia. “Armstrong’s engineering team is highly inspired to co-design and manufacture advanced medical devices, and we look forward to producing the device at scale to serve the millions of patients suffering from ADHD.”
Health Technology Insights: Soleo Health Names Jody Thompson SVP of Rare Disease Business Development
In November 2025, NeuroSigma announced successful completion of its pilot commercialization program for the first-generation Monarch eTNS device. During the pilot phase, the company dispensed over 1,000 Monarch devices and over 100,000 of the daily disposable patches. Based on strong market demand, NeuroSigma is preparing to launch the second-generation Monarch eTNS device in late Q1 2026.
“Completion of this investment marks a significant milestone for NeuroSigma, Armstrong, and Checkmate,” said Tom Paschall, CEO of Checkmate Capital and NeuroSigma Director. “Within the medical device industry, we see favorable conditions for the external neurostimulation sector and the central nervous system therapeutics market in general. The Monarch eTNS device is a groundbreaking neuro-electronic product that provides patients, families, and physicians with an alternative to stimulant medications and the negative side effects associated with them.”
Health Technology Insights: Amphista Reveals AMX-883 Preclinical Data for AML Therapy
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- GlobeNewswire
